CorMedix, Inc. (CRMD)
8.39
+0.11
(+1.33%)
USD |
NASDAQ |
Aug 25, 13:05
CorMedix Enterprise Value : 530.88M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 530.88M |
| August 21, 2026 | 524.67M |
| August 20, 2026 | 527.00M |
| August 19, 2026 | 549.52M |
| August 18, 2026 | 522.34M |
| August 17, 2026 | 483.51M |
| August 14, 2026 | 473.41M |
| August 13, 2026 | 520.01M |
| August 12, 2026 | 439.24M |
| August 11, 2026 | 454.77M |
| August 10, 2026 | 472.63M |
| August 07, 2026 | 465.64M |
| August 06, 2026 | 471.08M |
| August 05, 2026 | 463.31M |
| August 04, 2026 | 471.86M |
| August 03, 2026 | 474.19M |
| July 31, 2026 | 472.63M |
| July 30, 2026 | 469.53M |
| July 29, 2026 | 446.23M |
| July 28, 2026 | 458.65M |
| July 27, 2026 | 478.07M |
| July 24, 2026 | 499.04M |
| July 23, 2026 | 513.02M |
| July 22, 2026 | 504.48M |
| July 21, 2026 | 523.89M |
| Date | Value |
|---|---|
| July 20, 2026 | 492.05M |
| July 17, 2026 | 541.76M |
| July 16, 2026 | 531.66M |
| July 15, 2026 | 541.76M |
| July 14, 2026 | 530.11M |
| July 13, 2026 | 533.99M |
| July 10, 2026 | 540.20M |
| July 09, 2026 | 561.17M |
| July 08, 2026 | 573.60M |
| July 07, 2026 | 576.71M |
| July 06, 2026 | 570.49M |
| July 02, 2026 | 567.39M |
| July 01, 2026 | 545.64M |
| June 30, 2026 | 497.49M |
| June 29, 2026 | 565.08M |
| June 26, 2026 | 581.55M |
| June 25, 2026 | 571.35M |
| June 24, 2026 | 623.88M |
| June 23, 2026 | 640.34M |
| June 22, 2026 | 657.59M |
| June 18, 2026 | 645.83M |
| June 17, 2026 | 645.83M |
| June 16, 2026 | 645.05M |
| June 15, 2026 | 639.56M |
| June 12, 2026 | 651.32M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Innoviva, Inc. | 1.218B |
| Zevra Therapeutics, Inc. | 471.26M |
| Filana Therapeutics, Inc. | -37.75M |
| Eloxx Pharmaceuticals, Inc. | 18.72M |
| Cannabis Global, Inc. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 25.99M |
| Revenue (Quarterly) | 101.93M |
| Total Expenses (Quarterly) | 75.94M |
| EPS Diluted (Quarterly) | 0.281 |
| Gross Profit Margin (Quarterly) | 75.66% |
| Profit Margin (Quarterly) | 25.50% |
| Earnings Yield | 25.08% |
| Operating Earnings Yield | 28.30% |
| Normalized Earnings Yield | 26.25 |